
STATUTORY INSTRUMENTS

2009 No. 3209

The Misuse of Drugs Act 1971 (Amendment) Order 2009

Amendments to the Misuse of Drugs Act 1971

2.—(1) Schedule 2 to the Misuse of Drugs Act 1971 (which specifies the drugs which are subject to control under that Act) is amended as follows.

(2) In Part 2 (Class B drugs)—

(a) after paragraph 1(b), insert—

“(c) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone.

3-Dimethylheptyl-11-hydroxyhexahydrocannabinol.

[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate.

9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[*c*]chromen-1-ol.

Nabilone.

Any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”;

- (b) in paragraph 2A, after “derivative” insert “or of a substance for the time being specified in paragraph 1(c) of this Part of this Schedule.”.
- (3) In Part 3 (Class C drugs)—
- (a) in paragraph 1(a), after “Flurazepam”, insert “Gamma-butyrolactone”;
- (b) in paragraph 1(b)—
- (i) before “4-Androstene-3,17-dione”, insert—
“5 α -Androstane-3,17-diol.
Androst-4-ene-3,17-diol.
1-Androstenediol.
1-Androstenedione”;
- (ii) after “4-Androstene-3,17-dione”, insert “5-Androstenedione.”;
- (iii) after “Boldenone.”, insert “Boldione.”;
- (iv) after “Bolmantalate.”, insert “1,4-Butanediol.”;
- (v) after “Clostebol.”, insert—
“Danazol.
Desoxymethyltestosterone”;
- (vi) after “Furazabol.”, insert—
“Gestrinone.
3-Hydroxy-5 α -androstan-17-one.”;
- (vii) after “Nandrolone.”, insert “19-Norandrostenedione.”;
- (viii) after “19-Nor-5-Androstene-3,17-diol”, insert “19-Norandrosterone.”;
- (ix) after “Norethandrolone.”, insert—
“19-Noretiocholanolone.
Oripavine.”;
- (x) after “Propetandrol.”, insert “Prostanozol.”;
- (xi) after “Testosterone.”, insert “Tetrahydrogestrinone.”;
- (c) after paragraph 1(c), insert—
“(ca) 1-benzylpiperazine or any compound structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways—
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
- (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl groups.”;
- (d) in paragraph 1(e), after “Somatropin.”, insert “Zeranol.” and “Zilpaterol.”.